PR Newswire
LONDON, United Kingdom, February 16
16 February 2026
4basebio PLC
(«4basebio» or the «Company»)
Director Dealing
Cambridge, UK, 16 February 2026 – 4basebio PLC (AIM: 4BB), an innovation driven
biotechnology company enabling and accelerating development of advanced therapy
medicinal products (ATMPs) through its high performant GMP-grade synthetic DNA
products, announces that on 13 February 2026 it was informed that Dr. Amy
Walker, Chief Executive Officer of the Company made the following purchase in
ordinary shares in the capital of the Company through the market.
Further details are set out in the Notification of Dealing Form below.
Director Number Purchase Shareholding Shareholding
/ PCA of Price Following Following
Ordinary (Aggregated) Acquisition Acquisition as
Shares (p) a Percentage of
Acquired Issued Share
Capital
Dr. Amy 2,650 586.08 46,666 0.30%
Walker
The 2,650 shares purchased represent approximately 0.02 per cent. of the
Company’s issued share capital.
The issued share capital of the Company comprises 15,538,518 ordinary shares.
This announcement contains inside information for the purposes of Article 7 of
EU Regulation 596/2014 as amended by regulation 11 of the Market Abuse
(Amendment) (EU Exit) Regulations 2019/310.
For further enquiries, please contact:
4basebio PLC +44 (0)12 2396 7943
Dr Amy Walker, CEO
Cairn Financial Advisers LLP (Nominated Adviser) +44 (0)20 7213 0880
Jo Turner / Sandy Jamieson / Ed Downes
Cavendish Capital Markets Limited (Joint Broker) +44 (0)20 7220 0500
Geoff Nash / Nigel Birks
RBC Capital Markets (Joint Broker) +44 (0)20 7653 4000
Kathryn Deegan / Matthew Coakes +44 (0)203 707 5700
ICR Healthcare (Media and Investor Relations)
Mary-Jane Elliott / Jessica Hodgson
Notes to Editors
About 4basebio
4basebio (AIM: 4BB) is an innovation driven life biotechnology company focused
on accelerating the development of advanced therapy medicinal products (ATMPs)
through its high-performance synthetic DNA products and non-viral, cell
targeting nucleic acid delivery platform. The Company’s objective is to become a
market leader in the manufacture and supply of high-quality synthetic DNA
products for research, therapeutic and pharmacological use as well as
development of target specific non-viral vectors for the efficient delivery of
payloads in patients.
Forward-looking statements
This announcement may contain certain statements about the future outlook for
4basebio. Although the directors believe their expectations are based on
reasonable assumptions, any statements about future outlook may be influenced by
factors that could cause actual outcomes and results to be materially different.
Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them
1 Details of the persons discharging
managerial responsibilities / person
closely associated
a) Name Dr. Amy Walker
2 Reason for the notification
a) Position/Status Chief Executive Officer
b) Initial notification/ Amendment Initial notification
3 Details of the issuer, emission
allowance market participant, auction
platform, auctioneer or auction
monitor
a) Name 4basebio plc
b) LEI 213800E2DX9EAIUNCB30
4 Details of the transaction(s): section
to be repeated for (i) each type of
instrument; (ii) each type of
transaction; (iii) each date; and (iv)
each place where transactions have
been conducted
a) Description of the Ordinary Shares
financialinstrument, type ISIN: GB00BMCLYF79
ofinstrumentIdentification code
b) Nature of the transaction Acquisition of ordinary shares
c) Price(s) and volume(s)
Price(s) Volume(s)
586.08p 2,650
d) Aggregated information 2,650586.08p
– Aggregated volume
– Aggregated Price
e) Date of transaction 13 February 2026
f) Place of transaction London Stock Exchange
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/4basebio-plc/r/director-dealing,c4307985
